AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01285752
Drug: AK106-001616
RxNorm normalized name: AK106-001616
DrugBank: AK106-001616 (DB16058)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01285752
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02971007
Drug: Oral Encochleated Amphotericin B (CAMB)
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lipid-crystal nano-particle formulation amphotericin B
Trial: NCT02971007
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03634293
Drug: Alirocumab Injectable Product
RxNorm normalized name: alirocumab Injectable Product
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
Trial: NCT04083833
Drug: Tetrodotoxin
RxNorm normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single TTX dose in a dose ascending study
Trial: NCT03634293
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
Trial: NCT00486512
Drug: 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00486512
Drug: placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00688623
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 5 mg tablets were supplied in blister packs
Trial: NCT00064623
Drug: Capsaicin Dermal Patch
RxNorm normalized name: capsaicin Medicated Patch
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02748395
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02748395
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00505518
Drug: Psychotropic medication (at discretion of psychiatrist)
RxNorm normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant medication, prescribed at discretion of psychiatrist
Trial: NCT01420926
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT01420926
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01867502
Drug: MET + Vildagliptin Group
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator.
Trial: NCT00439296
Drug: ABT-751
RxNorm normalized name: ABT-751
DrugBank: ABT-751 (DB12254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.
Trial: NCT00439296
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Treatment Course 1 only:~* 10 mg/m2/day divided BID.~* Take dexamethasone by mouth days 1-14.
Trial: NCT00439296
Drug: PEG-asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Treatment Course 1:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on day 15.
Trial: NCT02620124
Drug: Natural cycle: Triptorelin acetate 0.1 mg
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
Trial: NCT02620124
Drug: Hormone replacement cycle and triptorelin acetate 0.1 mg
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
Trial: NCT00439296
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Given Intrathecally on day 1 of course 1 at the dose defined by age below.~  * 30 mg for patients age 1-1.99~ * 50 mg for patients age 2-2.99~ * 70 mg for patients \>3 years of age~* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.
Trial: NCT00439296
Drug: 6-thioguanine
RxNorm normalized name: 6-thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
Trial: NCT02637583
Drug: PPV23
RxNorm normalized name: pneumococcal polysaccharide PPV23
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
Trial: NCT01209351
Drug: teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: teduglutide 4 mg
Trial: NCT00585455
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: open label 25-50 mg daily as tolerated
Trial: NCT03236792
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
Trial: NCT01627041
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01627041
Drug: Daunorubicin Hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00613496
Drug: irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
Trial: NCT01460134
Drug: CDX-1127
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.
Trial: NCT01460134
Drug: CDX-1127
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
Trial: NCT01460134
Drug: CDX-1127
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
Trial: NCT01340586
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 5 mg, Once, 4 days
Trial: NCT01340586
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 5 mg, Twice, 15 days
Trial: NCT04068246
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly
Trial: NCT03478696
Drug: budesonide/formoterol
RxNorm normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
Trial: NCT03478696
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
Trial: NCT03478696
Drug: placebo to match tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
Trial: NCT01627041
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04568200
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500mg i.v. day 1-22-43-64
Trial: NCT04568200
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT04568200
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy
Trial: NCT01380366
Drug: Somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
Trial: NCT00997893
Drug: Medroxyprogesterone Acetate (MPA)
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medroxyprogesterone acetate (MPA) (10mg)
Trial: NCT00234442
Drug: Iressa (Gefitinib)
RxNorm normalized name: Iressa
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01981850
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00431431
Drug: tibolone
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years treatment with tibolone (1.25 mg Org OD-14)
Trial: NCT00431431
Drug: raloxifen
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 years treatment with raloxifene (60 mg)
Trial: NCT00797810
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01006551
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
Trial: NCT00765492
Drug: AZD8529
RxNorm normalized name: AZD8529
DrugBank: AZD8529 (DB16073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02372461
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin Liquid
Trial: NCT03824002
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
Trial: NCT03824002
Drug: Aspart insulin
RxNorm normalized name: Aspart Insulin
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Trial: NCT03824002
Drug: Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Trial: NCT03824002
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Trial: NCT03824002
Drug: Repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Trial: NCT04427865
Drug: prophylactic lactoferrin daily
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral lactoferrin daily
Trial: NCT02588235
Drug: Ezetimibe and Atorvastatin
RxNorm normalized name: Ezetimibe and Atorvastatin Tablets
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
Trial: NCT02588235
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin (20 mg/day）
Trial: NCT00003425
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003900
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003900
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04801836
Drug: Estetrol monohydrate 15 mg
RxNorm normalized name: estetrol monohydrate
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One Estetrol monohydrate (E4) 15 mg tablet once per day
Trial: NCT00003425
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00977171
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
Trial: NCT01764711
Drug: Cosyntropin administration
RxNorm normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
Trial: NCT03796637
Drug: Ataluren
RxNorm normalized name: Ataluren
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Trial: NCT00100100
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02955524
Drug: Tetracaine 0.5%
RxNorm normalized name: TETRACAINE 0.5% VISCOUS (FORTE) OPH SOLN
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
Trial: NCT02955524
Drug: Lidocaine hydrochloride ophthalmic gel 3.5%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
Trial: NCT01847651
Drug: LOLA or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
Trial: NCT02558218
Drug: Systane Ultra
RxNorm normalized name: Systane Ultra
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
Trial: NCT04176367
Drug: Nicergoline from China
RxNorm normalized name: China-Gel
DrugBank: Nicergoline (DB00699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the test arm of China local manufactured Nicergoline
Trial: NCT04176367
Drug: Nicergoline from Italy
RxNorm normalized name: nicergoline
DrugBank: Nicergoline (DB00699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the reference arm of Italy originator Nicergoline.
Trial: NCT01989910
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir 400mg oral twice daily
Trial: NCT01989910
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz 600mg oral at bedtime
Trial: NCT02747732
Drug: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT
Trial: NCT01891968
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
Trial: NCT01511471
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90mg twice a day for 15 days
Trial: NCT01174199
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01174199
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01051687
Drug: Botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit.
Trial: NCT00412893
Drug: Isavuconazole
RxNorm normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
Trial: NCT00412893
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
Trial: NCT01230463
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
Trial: NCT01230463
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.